Pain in malignant pleural mesothelioma: a prospective characterisation study. by MacLeod, Nicholas et al.
Title: Pain in malignant pleural mesothelioma: a prospective characterisation study 
Running head: Pain in mesothelioma

Authors: N MacLeod 1,2, C Bray 2, J Stobo 2, L McMahon2, D Taggart2, M Fallon1* and B J Laird 1,2,3*. 
1 Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh UK; 2 Beatson West of Scotland Cancer Centre, Glasgow, UK; 3European Palliative Care Research Centre, Norwegian University of Science and Technology, Trondheim, Norway.
*joint senior authors
Corresponding Author: Dr Barry Laird, Edinburgh Cancer Research Centre, University of Edinburgh, Western General Hospital, Edinburgh. EH4 2XR.
Email: Barry.laird@ed.ac.uk
T: 0044 131 651 8600
F: 0044 131 777 3564

Article Type: Original Article

Funding: The clinical trial was funded by grants from the June Hancock Mesothelioma Research Fund and the Beatson Cancer Charity.  

Conflicts of Interest: There are no conflicts of interest to declare
Clinical Trial Registration: ISRCTN 10644347
What is already known about this topic?
Pain due to mesothelioma is often difficult to control and often requires multiple analgesics. An understanding of pain in mesothelioma and its underlying neurobiology may guide clinicians in the appropriate treatments. 
What does this study add?
This is the first study to characterise mesothelioma related pain. Mesothelioma-related pain is often severe and interferes with function. Pain which has a neuropathic component is only present in half of patients, however was associated with more intense pain.  No features were predictive of response to radiotherapy. A detailed pain assessment in mesothelioma is necessary to guide analgesic treatment.
Abstract

Introduction: Malignant pleural mesothelioma (MPM) is associated with severe pain. The underlying neurobiology of this is complex. The primary aim of this study was to characterise pain in MPM.  

Methods: This study was undertaken as part of a trial examining radiotherapy for the treatment of pain in MPM (ISRCTN 10644347). Patients had MPM with associated pain for which radiotherapy was planned and a worst pain score > 4/10. The following assessments were undertaken: Clinical neuropathic pain assessment; Brief Pain Inventory (BPI); Leeds Assessment of Neuropathic Symptoms and Signs (LANSS); Short form of the McGill Pain Questionnaire (SF-MPQ); Quantitative Sensory Testing (QST). The relationship of these characteristics and response to radiotherapy was assessed. Unless stated medians and (interquartile range (IQR)) are used.  

Results: Thirty-seven were recruited. Average pain and worst pain was 4 (4-6) and 8 (6-8) respectively. Higher average pain and higher worst pain scores were associated with higher interference scores on the BPI, p<0.001 and p<0.0005. Twenty patients (54%) had a clinical diagnosis of neuropathic pain and of these only 6 patients (40%) screened positively for neuropathic pain using the LANSS. Patients with a high LANSS also had higher BPI and SF-MPQ’s. The presence of neuropathic pain (clinically or by LANSS) didn’t predict response to radiotherapy, p<0.05.  The SF-MPQ scores were higher in those with abnormal cool sensation on QST  (p=0.016). 

Conclusion: Pain in mesothelioma varies between patients and may have neuropathic components. An adequate pain assessment is necessary to guide the clinician in the appropriate choice of analgesics.



Introduction

Malignant pleural mesothelioma (MPM) is an uncommon cancer but is associated with significant morbidity and mortality. The UK has the highest incidence of MPM in the world and this figure is expected to peak in the next few years. ADDIN EN.CITE [, ] Of all the symptoms associated with MPM, pain is the most common and the most challenging to treat. ADDIN EN.CITE [, ]  Patients often have uncontrolled pain despite multiple analgesics and one of the reasons for this is that the underlying pathophysiology and resultant neurobiology is complex. Pain may be due to tumour infiltration of the chest wall, ribs, nerve roots, intercostal nerves, neurovascular bundle or a combination of these. The associated pro-inflammatory cytokine response and other tumour mediated factors may complicate further the neurobiological process. In addition, in patients who undergo surgery, post thoracotomy pain is often present.[] The pain associated with MPM is often more severe and difficult to treat than pain caused by lung cancer.[] 

In the clinic, pain associated with MPM is presumed to be due to bone and neuropathic pain mechanisms. In cancer, the effect of malignant invasion of bone resulting in pain is not wholly understood but is thought to be primarily initiated through nociceptors in the periosteum.[] In the setting of neuropathic pain, while primary injury of the nervous system is required, ongoing nociceptive stimulation results in recruitment of non-nociceptive receptors resulting in pain from non-noxious stimuli and leading to a central sensitisation.[] As a result analgesics which target different pain mechanisms are often required however the clinical characteristics of cancer pain of mixed mechanisms has not been well described. Furthermore the clinical characterisation of pain in MPM has not been described.

An improved understanding of these clinical characteristics may inform the choice of analgesic therapy (including radiotherapy) in MPM. Furthermore if factors were identified which predicted those patients more likely to respond to radiotherapy, then treatment could be directed appropriately.


Therefore, the primary aim of the present study was to characterise pain in MPM. A secondary aim was to establish if any pain characteristics were predictive of those patients who were more likely to respond to radiotherapy for treatment of pain related to MPM. 

Methods
This study was undertaken as part of a larger trial examining the role of radiotherapy for the treatment of pain in MPM (ISRCTN 10644347), the findings of which are presented elsewhere.[] The study followed the procedures of the Declaration of Helsinki and Good Clinical Practice. Patients were recruited from three UK cancer centres: the Beatson West of Scotland Cancer Centre Glasgow, the Edinburgh Cancer Centre in Edinburgh and Weston Park Hospital in Sheffield. Ethical approval was obtained and all patients provided written informed consent.

Eligible patients met the following criteria: 18 years of age or over; a diagnosis of MPM (histological or multidisciplinary team); mesothelioma related pain* (> 4/10 (0-10 Numerical Rating Scale)) for which radiotherapy was planned (based on a decision made by the treating oncologist that pain was sufficient); a life expectancy of at least three months and a performance status of 0-2 (Eastern Cooperative Oncology Group – ECOG). Patients were recruited from June 2012 until December 2013. 
*Mesothelioma related pain was defined as chest wall pain that was felt to be due to mesothelioma based on clinical judgment. Patient who had received chemotherapy in the preceding 6 weeks were excluded to minimise any effect of this on the pain.

There was no specific requirement regarding analgesics prior to study entry. However, patients were assesses by a palliative medicine consultant on at least one occasion prior to study entry in an attempt to optimise analgesia. Weak and strong opioids were defined as per the WHO analgesic ladder for cancer pain relief.[] In all patients the primary indication for taking an opioid was mesothelioma related pain, and patients had been titrated to maximal tolerable dose but by definition still had sub-optimal pain control (>4/10 on a 0-10 Numerical Rating Scale).

Patients were excluded from the study if they had received chemotherapy or radiotherapy in the preceding six weeks that was likely to alter pain during the duration of the study. Patients in whom chemotherapy was planned during the study period were also excluded.

The diagnosis of neuropathic pain was made clinically. This was informed by knowledge of the underlying disease, a detailed pain history (including patient volunteered descriptors) and supported by positive (e.g. spontaneous pain, allodynia, hyperalgesia) or negative (e.g. sensory loss) features suggestive of neuropathic pain.

Procedures
All patients underwent a detailed clinical pain assessment and completed the following questionnaires: the Brief Pain Inventory (BPI), Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) and the Short form McGill Pain Questionnaire (SF-MPQ). Where a clinical diagnosis of neuropathic pain was made, this was noted. Patients also underwent psychophysical tests using Quantitative Sensory Testing (QST). All assessments were performed prior to radiotherapy. 

Brief Pain Inventory
The BPI is a multi-dimensional pain assessment tool which assesses intensity and interference of pain on daily function (e.g. sleep, mood, relationships,work). It was developed for use in cancer patients and has been extensively validated in both cancer and non-cancer patients. ADDIN EN.CITE [] The individual components of the intensity and interference subscales can be assessed in isolation or in combination. In the present study a clinically meaningful improvement in pain was defined as a 30% drop in total BPI score at week 5 (study endpoint)  from baseline.[]

McGill Pain Questionnaire
The SF-MPQ has been validated in neuropathic and non-neuropathic pain to rate the intensity and quality of pain.  ADDIN EN.CITE [] 

Leeds Assessment for Neuropathic Symptom Score (LANSS)
The LANSS was developed in 2001, in chronic non-malignant pain,  to identify patients who are likely to have a neuropathic component to their pain.[] It has been also been assessed for use in cancer pain. ADDIN EN.CITE [, ] The assessment consists of two sections; a pain questionnaire and sensory testing. In the pain questionnaire, subjects are asked five “yes/no” questions concerning their pain. With the sensory testing, the subject is examined for allodynia and for altered pin-prick threshold. Combining the scores for the questionnaire and the sensory testing gives a maximum score of 24. A score of >12 suggests that neuropathic mechanisms are likely to be contributing to the patient’s pain whereas a score of <12 suggests that neuropathic mechanisms are unlikely to be contributing to the patient’s pain.

Quantitative Sensory Testing
QST is a form of psychophysical testing to define the underlying mechanisms of pain and augments the traditional neurological examination. Its use in the characterisation and assessment of pain relies on what is known about the plasticity of the nervous system. ADDIN EN.CITE [] QST has been used most frequently in the assessment of neuropathic pain for measuring sensory responses to defined thermal and mechanical stimuli. ADDIN EN.CITE [, ] It has been shown that abnormalities of some aspects of QST (warm/cold stimuli) predict patients who are more likely to respond to radiotherapy for the treatment of cancer induced bone pain. ADDIN EN.CITE []   It is therefore of interest to explore if a paradigm exists in patients receiving radiotherapy for MPM related pain. The techniques used in QST testing for this study have been described previously. ADDIN EN.CITE [] 

Statistics and analysis
All questionnaires were completed by the patient in the presence of the same clinician, who also undertook QST, in order to reduce inter-observer variability. 

Patient demographics and pain characteristics (SF-MPQ, BPI) were summarised using proportions, means and standard deviations (SDs) or medians and inter-quartile ranges (IQRs) as appropriate. BPI “average pain” and “worst pain” scores were related to the BPI interference scale using Spearman’s correlation. A further analysis of the BPI interference scale was undertaken to compare those patients with, and those without, neuropathic pain, using Mann–Whitney tests.  

Results
Forty patients consented to the study, 37 of whom completed the assessments. The characteristics of all patients are shown in Table 1. The median age was 71.5 years (IQR 65-76) and median time from diagnosis to study entry was approximately four months (IQR 2-12). All patients were performance status 0-2. Epithelioid MPM was the most common histology, being present in 21 (56.8%) patients. Fourteen patients had completed platinum/pemetrexed based chemotherapy. 11 patients (28.9%) had metastatic disease at the time of study entry.




 
Analgesic use is shown in Table 2. Strong opioids were used by 32 patients (84.2%) whereas only three patients (7.9%) were on weak opioids. Twenty five patients (65.8%) were on adjuvant analgesics with the same number of patients on simple analgesics. Of those patients on adjuvant analgesics, 14 were on pregabalin, eight on gabapentin and three on amitriptyline. It is difficult to assess the impact that these analgesics had on the pain but, given that all these patients still had pain sufficient to require radiotherapy, it would imply that these drugs were not adequately controlling the pain.


Pain characteristics

The sensory component of the SF-MPQ is shown in Figure 1. The words most commonly chosen to describe the pain were aching, tender and sharp being reported by 32 (86.5%), 29(78.4%) and 27(73%) of patients respectively.  




  

Figure 2 shows the individual components of the BPI.  The median (IQR) for average pain and worst pain was 4 (4-6) and 8 (6-8) respectively. General activity, normal work and enjoyment of life scored the highest on the interference scores. Relationships appeared to be relatively unaffected by pain in this group.


Figure 3 shows scatterplots of the mean interference scores (MIS) measured against worst pain score (WPS) and average pain score (APS) from the BPI. The Spearman’s Correlation Coefficient for the MIS and the WPS was 0.567, p<0.001. The Spearman’s Correlation Coefficient for MIS and APS was 0.556, p<0.001. This shows a moderate positive association in worst and average pain scores with the mean interference score of the BPI. 

LANSS
Eleven patients, 31.4%, had a total LANSS >12 while 24 (68.6%) patients, had a LANSS <12. An analysis was performed to assess whether there was any association between LANSS, BPI and SF-MPQ.  

The median total BPI for patients with a LANSS <12 was 52 (IQR 41.00 - 59.50) versus 69.50 (IQR 61.00 – 84.00) for patients with a LANSS >12, p=0.004. Similarly, comparing the LANSS with the SF-MPQ, the median SF-MPQ for those with a LANSS <12 was 10.00 (IQR 8.00 – 13.50) versus 15.00 (IQR 12.00 – 18.00) for patients with a LANSS >12, p=0.012. These data show that patients with a high LANSS also have a high BPI and a high SF-MPQ  (see Figure 4), Spearman’s correlation coefficient 0.56 (p<0.001). 

Response to radiotherapy was assessed looking at baseline LANSS and SF-MPQ. There was no evidence that likelihood of response to radiotherapy is determined by the LANSS or SF-MPQ, p>0.05. 

A clinical diagnosis of neuropathic pain was made in 20 patients. Of the 11 patients with a positive LANSS score, eight also had a clinical diagnosis of neuropathic pain (73%). However, 11 of 24 patients with a LANSS <12 also had a clinical diagnosis of neuropathic pain (45.8%) suggesting that the LANSS may not be a particularly effective screening tool in this patient group given the high false negative rate. Furthermore, a clinical diagnosis of neuropathic pain did not predict response nor lack of response to radiotherapy with six patients with a clinical diagnosis of neuropathic pain responding and eight patients without such a clinical diagnosis responding. 

QST results
All QST parameters assessed in the hemithorax affected by MPM were compared to the contralateral side. These data are presented in Table 3. Abnormal sensation to brush stimuli was seen in n=13 (50%) of patients. Detection threshold was altered in n=29 (87.9%) of patients.  Pain threshold was abnormal in n=16 (78.8%) of patients. Sensation to cold stimuli was abnormal in n=24 (75%) of patients, and abnormal to the warm stimuli in n=19 (59.4%) of patients. Pin prick sensation was abnormal in n=19 (63.4%). Finally, in terms of wind up, this was abnormal in n=21 (70%) of patients. 


 
Further analyses were performed to ascertain whether there was an association between specific QST characteristics, namely pin prick, hot and cold sensation, and the scores obtained in the BPI, LANSS or SF-MPQ. The median SF-MPQ in those with abnormal QST cool sensation was 12 (IQR 9.5 – 16.5) compared with a median SF-MPQ of 6.5 (IQR 5.0 – 11.5) in those with normal cool sensation. This was a significant difference between those two groups of patients (p = 0.016). There was no such relationship between SF-MPQ and normal or abnormal hot sensation (p = 0.697). There was also no relationship between total BPI and any of the three selected QST assessments. With regards to the QST data and LANSS, all eight patients, in whom pin prick sensation was assessed, who had a LANSS >12 had abnormal pin prick sensation whereas only nine of the 20 patients (45%) with a LANSS <12 had abnormal pin prick sensation (p = 0.010). Analysis was also performed to investigate whether there were any particular QST characteristics which would suggest a higher likelihood of response to radiotherapy. No such association was seen.

Discussion
Pain is a significant problem in MPM and patients scored highly on all pain questionnaires.  Pain also significantly impacted on day to day function and high levels of worst and average pain were associated with functional interference. 

Pain in MPM has been reported as having a strong neuropathic component; related to its local effects on the neurovascular bundle.[] It was of interest that in the present study, only 20 patients (54%) had a clinical diagnosis of neuropathic pain and in such patients it would be reasonable to use appropriate neuropathic agents. Pain response to radiotherapy did not appear to be affected by whether there was a neuropathic element to the pain with a similar proportion of patients responding to radiotherapy in both groups. Of the 20 patients who had a clinical diagnosis of neuropathic pain, only eight had a positive LANSS. In addition, 11 of the 24 patients with a negative LANSS had a clinical diagnosis of neuropathic pain. Based on these data, it would appear that the LANSS is not a particularly effective screening tool for neuropathic pain in MPM. 

This is the first study that characterises pain in MPM, therefore, we are unable to compare our findings with other previous work. However, similar work has been performed on cancer-induced bone pain. ADDIN EN.CITE [] The work on CIBP showed that WPS was more closely correlated to MIS than APS. It is accepted that background pain in CIBP is easier to control than incident pain, but in MPM related pain, it would appear that both WPS and APS correlate with MIS suggesting that both background pain and incident pain are problematic in MPM patients. Therefore, the aim of analgesia should be to target background and incident pain.

With regards to the SF-MPQ descriptors, the most commonly used words in this study were aching, tender and sharp. In previous work examining CIBP, the most commonly used descriptors were dull, sore, hurting and heavy. ADDIN EN.CITE [] This would suggest that the character of pain in MPM is different and that in part this may be due to underlying its complex mechanism; nociceptive and neuropathic in combination.

QST has never been studied in MPM patients however have been studied in patients undergoing palliative radiotherapy for cancer induced bone pain. ADDIN EN.CITE [] In CIBP, the main finding was that those patients who had normalisation of abnormal warm sensation had higher improvements in pain scores. ADDIN EN.CITE [] This suggests that patients who have alteration in certain sensory characteristics are more likely to respond to radiotherapy. The present study did not show that any QST parameters predicted response to radiotherapy, despite marked sensory abnormalities in the affected side with the majority of patients having altered pinprick, warm and cool sensation as well as altered detection threshold; however the study was not powered to assess this. 

It has been demonstrated that pain in MPM improves following radiotherapy in approximately 50% of patients.[] Whilst these findings are encouraging it does mean that some patients who are treated with radiotherapy do not get an improvement in their pain. If biomarkers were identified which predicted those patients who were more likely to respond to radiotherapy, then this may allow treatment to be stratified accordingly. The present study does to not identify any factors however was not powered as such. Future studies examining radiotherapy for the treatment of pain in MPM should include biomarker collection to allow any predictive factors to be identified. 

Limitations
The small sample size is a clear limitation and thus limited inference can be made from the findings. The sample size was based on assessing response rates to radiotherapy, as part of the primary study. All of the present aims were exploratory and should be examined further in larger cohorts. Another limitation is that the LANSS is a screening tool for neuropathic pain and not diagnostic; and again limited inference can be drawn. However there is no inter-observer variability as the same clinician undertook all assessments. 

The lack of a comparator arm is a limitation of the study as is the lack of temporal data. A comparator group would be of interest however would have been challenging to identify. Again temporal information would have been of interest but due to the attrition rate would have yielded limited information.

Conclusion
Pain is a common and severe problem in MPM which has a neuropathic component in some patients however clearly its mechanism is mixed. Of note there were no specific factors which predicted response and indeed the presence of neuropathic pain was not associated with any difference in pain relief from radiotherapy compared to relief in those patients without a neuropathic component. This is perhaps not surprising as the role of radiotherapy in the treatment of pain originating from predominantly neuropathic sources is not substantiated. 

It is important to identify factors predicting response to radiotherapy as the majority of patients who receive radiotherapy for MPM are in the last months of life. The identification of factors predicting response may enable treatment stratification. Studies assessing this are awaited with interest. 
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Figure Legends

Figure 1. Frequency of words used in the SF-SF-MPQ (Sensory component) to describe the pain, based on 37 completed baseline questionnaires.

Figure 2. Boxplots of visual analogue components from baseline BPI questionaire

Figure 3. Scatterplots of (a) worst pain score and (b) average pain score against interference score from baseline BPI questionaire

Figure 4. Boxplots of (a) total BPI and (b) MPG sensory scores at baseline split by LANSS category
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Table 1. Patient characteristics (n=40) 


Characteristic		n	%	Median	IQR
Male Sex		35	87.5		
ECOG
	0	3	7.5		
	1	18	45.0		
	2	19	47.5		
Time from diagnosis to study entry (days)				127	57-356
Mesothelioma
Histology	Epithelioid	21	56.8		
	Sarcomatoid	10	27		
	Mixed	3	8.1		
	Other	3	8.1		
	Not available	3			
Previous anti-cancer therapy for MPM	ChemotherapyRadiotherapy	141	36.82.5		
Clinical diagnosis of neuropathic pain	20	54		


Table 2. Number of patients taking each type of analgesia at baseline


Number of Patients	n	%
 Simple Analgesia   	25	65.8
Adjuvant Analgesia                                 	25	65.8
Weak Opioid               	3	7.9
Strong Opioid           	32	84.2
Adjuvant analgesic and strong opioid	24	64.9
Table 3. QST assessments of test versus control area at baseline.

	Increasedn(%)	Reducedn(%)	No different to control arean(%)	Missingn(%)	Totaln(%)
Brush	5 (19.2)	8 (30.8)	13(50.0)	14	40 (100.0)
Detection Threshold	12 (36.4)	17 (51.5)	4 (12.1)	7	40 (100.0)
Pain Threshold	11(33.3)	15 (45.5)	7(21.2)	7	40(100.0)
Cool	13 (40.6)	11 (34.4)	8 (25.0)	8	40 (100.0)
Warm	13 (40.6)	6 (18.8)	13 (40.6)	8	40 (100.0)
Pin Prick	8 (26.7)	11(36.7)	11(36.7)	10	40 (100.0)
	Present n(%)	Absent n(%)	No different to control arean(%)	Missingn(%)	Totaln(%)
Wind Up	6 (20.0)	15 (50.0)	9 (30.0)	10	40 (100.0)
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